DaVita Inc. DVA
At closeNov 12, 2026, 4:28 PM EST
After hours · Nov 12, 4:28 PM ET
- YTD
- +53.22%
- 1 year
- +40.83%
- Market cap
- 10.95B
- Revenue (ttm)
- 14.17B
- Profit margin
- 6.49%
- EPS (ttm)
- 13.21
- Shares out
- 62.90M
- P/E ratio
- 13.18
- Forward P/E
- 10.32
- YTD return
- +53.22%
- 1-year return
- +40.83%
- Volume
- 834.71K
- Avg volume
- 709.61K
- Open
- 180.90
- Previous close
- 183.50
- Day's range
- 174.01 – 181.96
- 52-week range
- 101.00 – 247.49
- Beta
- 0.86
- Analysts
- Buy
- Price target
- 222.29 (+27.7%)
- Earnings date
- Feb 1, 2027
5D -15.77 (-8.31%)
Key statistics
- Enterprise value
- 26.09B
- PEG ratio
- 0.45
- Price / sales
- 0.77
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 4.60%
- Free cash flow
- 905.08M
- Total cash
- 566.30M
- Total debt
- 13.39B
- Return on equity
- 96.79%
- Short % of float
- 16.30%
- 50-day average
- 182.90
- 200-day average
- 180.23
Analyst view
Consensus: buy
- Target (low)
- 165.00
- Target (mean)
- 222.29
- Target (high)
- 287.00
- Strong buy0
- Buy3
- Hold3
- Sell0
- Strong sell2
Next earnings
Feb 1, 2027
Expected Feb 1, 2027. Consensus EPS estimate 4.14.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 1, 2027 | Dec 30, 2026 | 4.20 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 3.57 | 3.82 | +0.25 | +7.00% |
| Aug 4, 2026 | Jun 30, 2026 | 3.88 | 4.02 | +0.14 | +3.61% |
| May 5, 2026 | Mar 31, 2026 | 2.41 | 2.87 | +0.46 | +19.09% |
| Feb 2, 2026 | Dec 31, 2025 | 3.24 | 3.40 | +0.16 | +4.94% |
| Oct 29, 2025 | Sep 30, 2025 | 3.17 | 2.51 | -0.66 | -20.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | UBS | main | Buy | Buy |
| Nov 2, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Nov 2, 2026 | TD Cowen | main | Buy | Buy |
| Aug 7, 2026 | TD Cowen | up | Hold | Buy |
| Aug 7, 2026 | Truist Securities | main | Hold | Hold |
| Aug 5, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
About DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Country
- United States
- Website
- davita.com
News
DVA Investors Have Opportunity to Join DaVita Inc. Fraud Investigation with SBS Law 
Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses 
Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses 
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA 
DaVita HealthCare (DVA) is a Top-Ranked Value Stock: Should You Buy? 
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA 
DaVita Inc. (DVA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript 
DaVita Sees Growth and Drug Savings Offsetting 2027 Reimbursement Pressure 
Lowey Dannenberg, P.C. is Investigating DaVita Inc. (NYSE: DVA) for Potential Violations of the Federal Securities Laws 
DaVita Inc. (DVA) Presents at 2026 UBS Global Healthcare Conference Transcript
Your note
Sign in to keep a note on DVA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ACKERMAN JOEL | Chief Financial Officer | Sale | May 6, 2026 | 132,434 |
| ARWAY PAMELA M. | Director | Stock Award(Grant) | Aug 13, 2026 | 27,223 |
| BERG CHARLES G | Director | Stock Award(Grant) | May 14, 2025 | 27,029 |
| BERKSHIRE HATHAWAY, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 26, 2026 | 0 |
| BERRY CHRISTOPHER MICHAEL | Officer | Stock Award(Grant) | Mar 12, 2026 | 19,640 |
| DESOER BARBARA J | Director | Stock Award(Grant) | Aug 13, 2026 | 14,299 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Berkshire Hathaway, Inc | 45.91% | 28,880,209 | 5.03B | Jun 29, 2026 |
| Blackrock Inc. | 3.91% | 2,460,987 | 428.53M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.34% | 2,101,425 | 365.92M | Jun 29, 2026 |
| Morgan Stanley | 2.55% | 1,601,710 | 278.91M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.19% | 1,377,914 | 239.94M | Jun 29, 2026 |
| State Street Corporation | 2.10% | 1,323,019 | 230.38M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Invesco Exchange-Traded Fund Trust-Invesco S&P 500 Equal Weight ETF | 1.70% | 1,068,917 | 186.13M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.62% | 1,019,274 | 177.49M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 1.32% | 830,137 | 144.55M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.17% | 736,440 | 128.24M | Jun 29, 2026 |
| NEUBERGER BERMAN EQUITY FUNDS-Neuberger Quality Equity Fund | 1.17% | 738,864 | 128.66M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 0.74% | 466,341 | 81.20M | Jun 29, 2026 |